Search Results for "Costs%20of%20Care"

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.

Meanwhile, pharmaceutical companies would stand to make a lot more money.

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal. 

This report was commissioned by Drug Pricing Lab.

Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today.

Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.

Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.

Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.

Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.

Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

According to the Drug Pricing Lab analysis, The Wall Street Journal published an article showing $9.1 billion retained by insurers over the course of 9 years from Medicare Part D plans.

U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.

What happens when a patient uses a copay coupon?

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.

A new analysis reviews several analyses of differential costs of care provided in the doctors office and hospital outpatient settings.

Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.

Members of Congress provided conflicting forecasts on how the agency's proposed pilot program of Part B drug payment might affect aspects of Medicare beneficiary care.

Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years.

Medicare is going to test new ways to reimburse doctors for medications, in hopes they'll choose less expensive drugs.

Drug prices have taken center stage since Turing Pharmaceuticals raised the price of its off-patent parasite-fighting drug Daraprim by over 5,000%.